170 related articles for article (PubMed ID: 37037668)
1. Management of luspatercept therapy in patients with transfusion-dependent β-thalassaemia.
Sheth S; Taher AT; Coates TD; Kattamis A; Cappellini MD
Br J Haematol; 2023 Jun; 201(5):824-831. PubMed ID: 37037668
[TBL] [Abstract][Full Text] [Related]
2. Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.
Taher AT; Cappellini MD; Kattamis A; Voskaridou E; Perrotta S; Piga AG; Filosa A; Porter JB; Coates TD; Forni GL; Thompson AA; Tartaglione I; Musallam KM; Backstrom JT; Esposito O; Giuseppi AC; Kuo WL; Miteva D; Lord-Bessen J; Yucel A; Zinger T; Shetty JK; Viprakasit V;
Lancet Haematol; 2022 Oct; 9(10):e733-e744. PubMed ID: 36007538
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics and Exposure-Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β-Thalassemia.
Chen N; Kassir N; Laadem A; Giuseppi AC; Shetty J; Maxwell SE; Sriraman P; Ritland S; Linde PG; Budda B; Reynolds JG; Zhou S; Palmisano M
J Clin Pharmacol; 2021 Jan; 61(1):52-63. PubMed ID: 32696522
[TBL] [Abstract][Full Text] [Related]
4. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
Cappellini MD; Viprakasit V; Taher AT; Georgiev P; Kuo KHM; Coates T; Voskaridou E; Liew HK; Pazgal-Kobrowski I; Forni GL; Perrotta S; Khelif A; Lal A; Kattamis A; Vlachaki E; Origa R; Aydinok Y; Bejaoui M; Ho PJ; Chew LP; Bee PC; Lim SM; Lu MY; Tantiworawit A; Ganeva P; Gercheva L; Shah F; Neufeld EJ; Thompson A; Laadem A; Shetty JK; Zou J; Zhang J; Miteva D; Zinger T; Linde PG; Sherman ML; Hermine O; Porter J; Piga A;
N Engl J Med; 2020 Mar; 382(13):1219-1231. PubMed ID: 32212518
[TBL] [Abstract][Full Text] [Related]
5. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia.
Piga A; Perrotta S; Gamberini MR; Voskaridou E; Melpignano A; Filosa A; Caruso V; Pietrangelo A; Longo F; Tartaglione I; Borgna-Pignatti C; Zhang X; Laadem A; Sherman ML; Attie KM
Blood; 2019 Mar; 133(12):1279-1289. PubMed ID: 30617198
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept.
Cappellini MD; Taher AT; Piga A; Shah F; Voskaridou E; Viprakasit V; Porter JB; Hermine O; Neufeld EJ; Thompson AA; Tang D; Yucel A; Lord-Bessen J; Yu P; Guo S; Shetty JK; Miteva D; Zinger T; Backstrom JT; Oliva EN
Eur J Haematol; 2023 Jul; 111(1):113-124. PubMed ID: 37095595
[TBL] [Abstract][Full Text] [Related]
7. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.
Kang C; Syed YY
Drugs; 2021 Jun; 81(8):945-952. PubMed ID: 33970460
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia.
Piga A; Longo F; Gamberini MR; Voskaridou E; Ricchi P; Caruso V; Pietrangelo A; Zhang X; Shetty JK; Attie KM; Tartaglione I
Ther Adv Hematol; 2022; 13():20406207221134404. PubMed ID: 36505885
[TBL] [Abstract][Full Text] [Related]
9. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
Cochrane Database Syst Rev; 2013 Aug; (8):CD004450. PubMed ID: 23963793
[TBL] [Abstract][Full Text] [Related]
10. Luspatercept for β-thalassemia: beyond red blood cell transfusions.
Taher AT; Cappellini MD
Expert Opin Biol Ther; 2021 Nov; 21(11):1363-1371. PubMed ID: 34404288
[TBL] [Abstract][Full Text] [Related]
11. Smad2/3-pathway ligand trap luspatercept enhances erythroid differentiation in murine β-thalassaemia by increasing GATA-1 availability.
Martinez PA; Li R; Ramanathan HN; Bhasin M; Pearsall RS; Kumar R; Suragani RNVS
J Cell Mol Med; 2020 Jun; 24(11):6162-6177. PubMed ID: 32351032
[TBL] [Abstract][Full Text] [Related]
12. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
13. Luspatercept: First Approval.
Markham A
Drugs; 2020 Jan; 80(1):85-90. PubMed ID: 31939073
[TBL] [Abstract][Full Text] [Related]
14. Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy.
Musallam KM; Taher AT; Kattamis A; Kuo KHM; Sheth S; Cappellini MD
Drug Des Devel Ther; 2023; 17():1583-1591. PubMed ID: 37255740
[TBL] [Abstract][Full Text] [Related]
15. Luspatercept in patients with non-transfusion dependent β-thalassaemia.
Platzbecker U; Morison JK
Lancet Haematol; 2022 Oct; 9(10):e709-e711. PubMed ID: 36007539
[No Abstract] [Full Text] [Related]
16. Luspatercept, a two-edged sword in beta-thalassemia-associated paravertebral extramedullary hematopoietic masses (EHMs).
Alashkar F; Klump H; Lange CP; Proske P; Schüssler M; Yamamoto R; Carpinteiro A; Berliner CA; Schlosser TW; Röth A; Reinhardt HC
Eur J Haematol; 2022 Dec; 109(6):664-671. PubMed ID: 36045599
[TBL] [Abstract][Full Text] [Related]
17. Oral deferiprone for iron chelation in people with thalassaemia.
Fisher SA; Brunskill SJ; Doree C; Chowdhury O; Gooding S; Roberts DJ
Cochrane Database Syst Rev; 2013 Aug; (8):CD004839. PubMed ID: 23966105
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U; Della Porta MG; Santini V; Zeidan AM; Komrokji RS; Shortt J; Valcarcel D; Jonasova A; Dimicoli-Salazar S; Tiong IS; Lin CC; Li J; Zhang J; Giuseppi AC; Kreitz S; Pozharskaya V; Keeperman KL; Rose S; Shetty JK; Hayati S; Vodala S; Prebet T; Degulys A; Paolini S; Cluzeau T; Fenaux P; Garcia-Manero G
Lancet; 2023 Jul; 402(10399):373-385. PubMed ID: 37311468
[TBL] [Abstract][Full Text] [Related]
19. Luspatercept: A Gigantic Step in the Treatment of Transfusion-Dependent β-Thalassemia Patients-a Quick Review.
Darvishi-Khezri H; Karami H
Adv Ther; 2021 Apr; 38(4):1732-1745. PubMed ID: 33661441
[TBL] [Abstract][Full Text] [Related]
20. Can N-acetylcysteine reduce red blood cell transfusion burden in patients with transfusion-dependent β-thalassemia?
Bahoush G; Rahab M; Ahmadvand P
Pediatr Hematol Oncol; 2024 May; 41(4):251-259. PubMed ID: 38088332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
